AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05722886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib in combination with cobimetinib
Description: Participants will receive vemurafenib at a dose of 960 mg (4 tablets of 240 mg) orally on a twice daily schedule throughout a 28-day cycle.~Participants will receive cobimetinib at a dose of 60 mg (3 tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break.~Participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent.
Study NCT05168462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced noradrenaline use
Description: Reduced noradrenaline by using a lower MAP target
Study NCT05372042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT Text Messages
Description: CBT skills based text messages delivered 3x per week for four weeks
Study NCT05372042 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT Text Messages
Description: CBT skills based text messages delivered 3x per week for four weeks
Study NCT05078541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Radiofrequency Ablation of Parotid Warthin's Tumor
Description: The Procedure~1. Injection of local subcutaneous and pericapsular anaesthesia~2. Needle radiofrequency ablation under ultrasound guidance~3. Patients should communicate with operating surgeon upon excessive heat or pain~4. The procedure usually lasts 30-45 minutes
Study NCT04699968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701，Famitinib
Description: SHR -1701, Intravenous ；Famitinib, oral
Study NCT04699968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: SHR -1701, Intravenous
Study NCT05015582 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pre op upper body forced air warming (32˚C)
Description: Use of upper body forced air warming at ambient (32˚C) for at least 30 minutes
Study NCT05015582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre op upper body forced air warming (32˚C)
Description: Use of upper body forced air warming at ambient (32˚C) for at least 30 minutes
Study NCT05015582 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pre op lower body forced air warming (32˚C)
Description: lower body forced air warming at ambient (32˚C) for at least 30 minutes
Study NCT05015582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre op lower body forced air warming (32˚C)
Description: lower body forced air warming at ambient (32˚C) for at least 30 minutes
Study NCT05015582 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pre op fluids (45˚C)
Description: fluids from warmed cabinet set at 45˚C
Study NCT05015582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre op fluids (45˚C)
Description: fluids from warmed cabinet set at 45˚C
Study NCT05015582 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra op upper body forced air warming (32˚C)
Description: Use of upper body forced air warming intra-operative at ambient (32˚C)
Study NCT05015582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra op upper body forced air warming (32˚C)
Description: Use of upper body forced air warming intra-operative at ambient (32˚C)
Study NCT05259111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home hospital
Description: Acute care provided at home, including nurse/paramedic visits, physician visits, laboratory testing, imaging, continuous monitoring, 24/7 urgent visits, and specialty consultation.
Study NCT05015582 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra op fluids at room temperature
Description: IV fluids at room temperature
Study NCT05015582 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra op upper body forced air warming at (32˚C)
Description: upper body forced air warming intra-operative at ambient (32˚C)
Study NCT05015582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra op upper body forced air warming at (32˚C)
Description: upper body forced air warming intra-operative at ambient (32˚C)
Study NCT05015582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra op upper body forced air warming at (42˚C)
Description: upper body forced air warming intra-operative at ambient (42˚C)
Study NCT05015582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra op lower body forced air warming at (32˚C)
Description: Lower body forced air warming intra-operative at ambient (32˚C)
Study NCT05015582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra op lower body forced air warming at (42˚C)
Description: Lower body forced air warming intra-operative at ambient (42˚C)
Study NCT04716738 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood analyses and coprological
Description: We will take a blood and stool sample
Study NCT05713591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition care model
Description: The transition care model (TC) consists in multidisciplinary standardized interventions to educate and support adolescents with congenital heart disease, representing a key element in the adequate delivery of care to these individuals during their transition from childhood to adulthood. This model encompasses three main pillars previously described.
Study NCT05760703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSG-0002 Injection
Description: Intravenous infusion
Study NCT05015582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra op fluid (42˚C)
Description: IV fluids with hotline fluid warmer set at 42˚C
Study NCT05407831 — intervention group
Intervention type: GENETIC
Intervention: Genetic
Description: Calculate MODY probability
Study NCT05407831 — intervention group
Intervention type: BEHAVIORAL
Intervention: Social habits
Description: Alcohol vs Smoking vs Drug use
Study NCT05407831 — intervention group
Intervention type: OTHER
Intervention: Perinatal stress
Description: Survey
Study NCT06196697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Subjects will receive AK104 by intravenous administration
Study NCT06196697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ivonescimab
Description: Subjects will receive AK112 by intravenous administration
Study NCT06196697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Subjects will receive AK104 and AK112 in combination with XELOX(oxaliplatin and capecitabine)
Study NCT06196697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX
Description: Subjects will receive AK104 and AK112 in combination withSOX(oxaliplatin and Tegafur)
Study NCT05329350 — intervention group
Intervention type: DEVICE
Intervention: muscular ventricular septal defects
Description: intervention cardiology and structural heart disease, including transseptal puncture.
Study NCT06415474 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lymphocyte Phenotyping Procedure
Description: For all patients, lymphocyte phenotyping will be performed on biological samples taken on D0, D7 and the day of discharge. In case of infection, phenotyping will also be performed on the day of infection diagnosis and on the day corresponding to half the duration of antibiotic therapy.~For phenotyping, only 1.5 mL will be used. In case of infection, an additional 1mL will be collected (0.5mL on the day of inclusion diagnosis and 0.5 mL on the day corresponding to half the duration of antibiotic therapy). Blood is collected during sampling, which takes place several times a day as part of the standard management of these patients.~It is important to note that phenotyping is not routinely performed as part of routine care. An additional tube is therefore taken specifically for this analysis, but this is done without the need for an additional puncture.
Study NCT05937516 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Nasotracheal intubation with conventionally
Description: Nasotracheal intubation will be applied conventionally to patients in this group.
Study NCT05937516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasotracheal intubation with angled ETT using guidewire
Description: a guide wire will be inserted into the ETT before intubation and angled 100-120 degrees to the distal end (in the shape of a hockey stick). The angulation will not be sharp but slightly curved and the apex of the angulation will be 2.5-3 cm proximal from the distal end. The ETT will be positioned perpendicular to the face and inserted into the nostril. After the angled part of the ETT passes through the nostrils, it will be directed to caudally according to the angle given to the tip of the ETT. Meanwhile, the ETT will be moved as a whole to prevent the ETT tip from contacting the posterior wall of the nasopharynx. When the ETT tip reaches the oropharynx, the guidewire will be removed and the rest of the intubation will be completed as in the conventional method.
Study NCT05768997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Derisomaltose Injection
Description: Ferric derisomaltose/iron isomaltoside (as iron) (0 weeks): 20mg/kg, diluted in 250ml of 0.9% physiological saline and injected intravenously over 30-60 minutes
Study NCT05768997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin Alfa Injection
Description: Darbepoietin alfa (0 weeks, 3 weeks, 6 weeks, 9 weeks): 6.75㎍/kg, subcutaneous or intravenous administration
Study NCT05768997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa Injection
Description: Darbepoietin alfa (0 weeks, 3 weeks, 6 weeks, 9 weeks): 6.75㎍/kg, subcutaneous or intravenous administration
Study NCT06181253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative education
Description: The intervention will be an instructional video describing proper walking technique particularly up flights of stairs for patients to do at home. This will be shown at preoperative surgical clinic and will be available for access at home from patient's cell phones. The video is currently in production at BMC. Additionally, text reminders will be sent daily to remind patients to walk at home.
Study NCT06181253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise
Description: Participants will be encouraged to compete 140-150 minutes of moderate aerobic exercise per week- achieved by two walking sessions per day 10-11 minutes in length (realistic/achievable goal)
Study NCT06181253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Text reminders will be sent daily to remind patients to walk at home.
Study NCT06181253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: Participants will be encouraged to walk 10,000 steps daily which will be tracked with a pedometer
Study NCT05603364 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 100ml carbohydrate containing 12.5g maltodextrin, fructose and glucose
Description: Drank 10.5% of 5 ml/kg body weight (100ml containing 12.5g maltodextrin, fructose and glucose) after extubation in the resuscitation room.
Study NCT05603364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine feeding
Description: Patients in group C were observed with 60min of abnormal vital signs after extubation, and returned to the ward for fasting and fasting for at least 6 h, and began to eat gradually through the mouth after anal exhaust
Study NCT04654910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROMIS Score Explanation
Description: The surgeon completing the clinical visit with the participant will explain what the PROMIS tool is, the purpose of the tool and what the participant's scores mean using a script.
Study NCT04654910 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will complete the PROMIS assessment but will not receive an explanation of the tool.
Study NCT05371366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASD closure with the novel occluder (ReAces)
Description: Transcatheter closure atrial septal defect with the novel occluder (ReAces)
Study NCT05371366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ASD closure with normal occluder
Description: Transcatheter closure atrial septal defect with normal occluder
Study NCT05733845 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Samples
Description: The intervention is to collect blood; urine; saliva and stool samples but also mucosal biopsies at each protocol visits (baseline and follow up visits).
Study NCT06137066 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 200mg GCE +200mg ALA
Description: 200mg green coffee extract + 200mg alpha-lipoic acid
Study NCT06137066 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 200mg GCE +400mg ALA
Description: 200mg green coffee extract + 400mg alpha-lipoic acid
Study NCT06137066 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 200mg GCE + 200mg DHB
Description: 200mg green coffee extract + 200mg dihydroberberine
Study NCT06137066 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose with 5 mg magnesium stearate and 5 mg silicon dioxide
Study NCT05243069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Technique
Description: Undergo 3D scanning
Study NCT06329986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAMER Lens Spectacle
Description: Regular daily wear of TAMER lens spectacle
Study NCT06329986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SV lenses
Description: SV lenses
Study NCT05661435 — intervention group
Intervention type: DEVICE
Intervention: RESP Biosensor
Description: The RESP Biosensor will be placed on the patient for periodic recording of auscultory sound.
Study NCT05408195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHATBOT use
Description: Patients benefiting from chemotherapy with outpatient follow-up (conventional follow-up by telephone calls) have the possibility to receive a weekly remote questionnaire (by email or SMS) via a CHATBOT on any terminal. This automated questionnaire collects data (completed by the patient and/or their caregivers) on tolerance and compliance to the care plan.
Study NCT06155097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transversus thoracis muscle plane block (TTP)
Description: patient in supine position with chest exposed and monitored by beat-to-beat arterial tracing and standard monitors. After determining the anterior T4-T5 interspace using US, the US probe places in the longitudinal plane 1 cm lateral to the sternal border. A parasternal sagittal view of the internal intercostal muscle and the transversus thoracis muscle between the fourth and fifth rib will be visualized above the pleura. A 22-gage needle will be inserted in plane to the transducer with the tip of the needle located in the TTP between the internal intercostal and transversus thoracis muscles. After excluding intravascular and intrapleural placement, LA will administer with intermittent aspiration (administration of 20 ml volume of local anesthetics (Lidocaine 2% +Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone) on each side. After block administration, the patients will be monitored for LA toxicity, hemodynamic instability, and allergic or unexpected adverse reactions for 20 minutes.
Study NCT06155097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: parasternal intercostal nerve block (PSI block)
Description: patient in supine position with chest exposed and monitored by beat-to-beat arterial tracing and standard. Ultrasound scan will be performed from lateral to medial in the intercostal space. The intercostal muscles and pleura will be identified along the lower border of the rib. At the lateral border of the sternum, internal thoracic vessels lying anterior to transverse thoracic muscle are identified. The needle will be inserted in-plane to follow its tip using 4-mL injections per intercostal space across levels two through six bilaterally, for a total of 40 mL (Lidocaine 2% +Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone)
Study NCT05763303 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: educational program
Description: interventional program consists of educational part and training part in case of agreement of participants
Study NCT05763303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational program
Description: interventional program consists of educational part and training part in case of agreement of participants
Study NCT05090527 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Risk stratification
Description: advanced penicillin challenge after risk stratification
Study NCT05689788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity laser therapy
Description: punctual technique on the 6 bilateral points of the cervical region and shoulder girdle, to be followed by a sweep technique on both trapezius muscles (upper portions). The parameters proposed by Dundar et al. will be used: an average power of 3 W, 60 J per point (360 J), and 500 J for manual scanning (1000 J). For the application of laser therapy, the 12 W BTL-6000 equipment that emits at 1064 nm wavelengths will be used.
Study NCT05689788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching exercise
Description: Three sets of bilateral passive static stretching will be performed for the upper trapezius, levator scapulae, and scalene muscles. Each series will last 30 seconds, followed by a 30-second rest interval. The exercises will be carried out with the participant in a seated position in a chair with a backrest.
Study NCT05689788 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Stretching exercise
Description: Three sets of bilateral passive static stretching will be performed for the upper trapezius, levator scapulae, and scalene muscles. Each series will last 30 seconds, followed by a 30-second rest interval. The exercises will be carried out with the participant in a seated position in a chair with a backrest.
Study NCT05689788 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham High-intensity laser therapy
Description: Intervention in which the therapist performs a HILT simulation application, performing all of the steps and movements for an administration without actually receiving the treatment.
Study NCT05438758 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Almond Therapy
Description: Participants will receive 12 remote session conducted by video or phone. Therapy sessions consist of modules selected using a shared decision making process, tailored so that it is personally meaningful to each participants. Participants will also receive supportive text messages on selective days over the 3 months.
Study NCT05438758 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intranasal ketamine (Esketamine)
Description: Participants will receive 56 mg or 84 mg once a week for 4 weeks followed by 56 mg or 84 mg once every two weeks for 8 weeks
Study NCT05438758 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants will continue to received the therapy that their treating physician felt was appropriate at the time of enrolment in the study. These can include cognitive behavioural therapy, supportive psychotherapy or mindfulness, support groups, physical activity or relaxation.
Study NCT04976647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HLX10+chemo
Description: HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle
Study NCT04976647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10+HLX07+chemo
Description: HLX07 1500mg IV q3w; HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle
Study NCT04976647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10+HLX07
Description: HLX07 1500mg IV q3w; HLX10 300mg IV Q3W;
Study NCT05222594 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Behavioral tasks during intracranial monitoring
Description: Participants will listen to sentences and stories while neural data are recorded through electrodes placed for clinical purposes.
Study NCT05494970 — intervention group
Intervention type: OTHER
Intervention: Accompaniment by the dental assistant.
Description: Inclusion visit (before radiotherapy treatment):~* oral hygiene education (prevention of complications related to radiotherapy) will be provided by the dental assistant.~* a written information guide on oral hygiene will be given to the patient.~* the questionnaire entitled Motivation and oral hygiene behavior will be completed by the patient.~End of study visit (three months post-radiotherapy):~• The Motivation and oral hygiene behavior and the satisfaction questionnaires will be completed by the patient.
Study NCT05411991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: UNa measurement after intravenous loop diuretic bolus
Description: Sodium concentration is measured on a urine spot sample, collected 30-120 min after administration of every protocol-specified intravenous bumetanide dose.
Study NCT05411991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous acetazolamide 500 mg OD
Description: Upfront use of intravenous acetazolamide 500 mg OD as part of the diuretic treatment, unless hypernatremia (>145 mmol/L) or metabolic acidosis (bicarbonate \<22 mmol/L) is present at the moment of the scheduled administration.